Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Regulatory Filings Classification · 12% confidence The document is a corporate press release announcing the completion of patient enrolment in a Phase II clinical trial. It contains no financial statements, no management or board changes, no dividend or financing details, and it is not a request for votes or a regulatory certification. It is a miscellaneous corporate announcement that does not fit any specific category, so it defaults to Regulatory Filings (RNS).
2026-05-18 English
Cosmo gibt Abschluss der Patientenrekrutierung für Phase-II-Studie des Programms zur Behandlung von distaler Colitis ulcerosa bekannt
Regulatory Filings Classification · 73% confidence The document is a corporate press release announcing the completion of patient recruitment for a Phase-II clinical trial. It does not contain financial statements or results, nor is it an AGM, earnings release, management change, or any other specialized filing. It is not introducing a new report publication, but rather providing operational/clinical program news. Therefore, it best fits the fallback category for general corporate/regulatory announcements.
2026-05-18 German
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which Are Statistically Significant
Regulatory Filings Classification · 75% confidence The document is an “ad hoc announcement pursuant to Art. 53 LR” (Swiss exchange ad-hoc disclosure) detailing Phase III clinical data and forward-looking statements. It is a corporate press release for regulatory disclosure of trial results rather than an earnings release, management change, capital transaction, director’s dealing, or formal investor presentation. It does not itself attach a separate financial report and is therefore a general regulatory announcement. This fits the fallback category Regulatory Filings (RNS).
2026-04-15 English
Daten der Phase-III-Studie über Zeitraum von 12 Monaten für Clascoterone 5% topische Lösung bestätigen positive Sicherheit bei chronischer Anwendung sowie anhaltendes Haarwachstum; beide Ergebnisse...
Regulatory Filings Classification · 82% confidence The document is an ad hoc press release under Swiss law (Art. 53 KR) announcing Phase-III clinical study results for Clascoterone, NDA/MAA filing plans, and investor events. It is not a financial earnings release, management or interim report, nor a presentation or detailed report itself. It serves as a general regulatory/market announcement. There is no vote result, share issue, M&A, or other specific category match. Therefore it falls into the fallback category of Regulatory Filings (RNS).
2026-04-15 German
Voting results of Cosmo’s 2026 AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a post-AGM announcement summarizing the voting results at Cosmo’s ordinary Annual General Meeting, including approval of items and the dividend. This clearly matches the category for official shareholder vote results at a general meeting.
2026-04-10 English
Abstimmungsergebnisse der Generalversammlung 2026 von Cosmo
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document provides the official voting results from Cosmo’s 2026 Annual General Meeting, detailing shareholder approvals, vote counts, and dividend resolutions. This clearly matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-04-10 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.